Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Content A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHWritten by Nathan Reiff. Article Posted: 2/12/2026. 
Summary - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings season is an opportunity for management to provide context beyond regulatory notices like FDA approvals. When healthcare companies release earnings on the same day, it can make for a busy period for investors trying to sort through the notable developments and plan trades. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors looking to act on these updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance U.K.-based pharma giant AstraZeneca ended 2025 by cementing its position as a go-to provider of cancer medicines, which accounted for about 44% of product sales in the quarter. Sales of oncology drugs such as Imfinzi and Enhertu rose as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the quarter. Net income rose to $10.2 billion from $7.0 billion in the prior-year quarter. The board declared a second interim dividend that is 7 cents higher than last year's. Investors should also watch AstraZeneca's robust clinical pipeline: management indicated 20 Phase 3 readouts are expected in 2026. The firm projects solid increases in both total revenue and core earnings per share (EPS) for full-year 2026. In the hours after its strong earnings performance, AZN shares climbed nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street has raised valuation questions: the consensus price target of $95.75 implies a potential decline of roughly 51% from then-current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Be Mindful of Earnings and Margin Limits Edwards builds replacement heart valves and related surgical systems. The firm's Q4 2025 results were largely positive, with sales up 13.3% YOY driven by strong transcatheter aortic valve replacement (TAVR) momentum and uptake of the latest SAPIEN valve iteration. However, adjusted EPS missed analyst expectations, and gross profit margin contracted by 0.8 percentage points year-over-year. Despite the mixed quarter, Edwards remains confident it can meet its prior 2026 outlook, which called for sales growth of 8%–10% YOY and EPS of $2.90–$3.05. In after-hours trading following the announcement, EW shares rose about 4% above the prior close to trade above $80. About two-thirds of analysts rate EW shares a Buy; the consensus price target of $96.77 implies roughly 25% upside from then-current levels. Orthopedic Demand Remains High, but Zimmer Faces Some Headwinds Zimmer Biomet, a maker of joint-replacement systems and orthopedic implants, saw its shares rise more than 3% after reporting EPS of $2.42, four cents above consensus, and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of estimates. Strong demand for orthopedic products supported both top- and bottom-line growth. Zimmer is also shifting focus to emphasize U.S. sales, where it generates close to 60% of its business. With insured patient utilization continuing to rise, near-term demand for its products is expected to remain healthy. Still, Zimmer faces headwinds from tariffs that could pressure EPS and revenue in 2026. Management issued conservative guidance in the latest earnings report, including adjusted EPS of $8.30–$8.45 and expected free cash flow growth of 8%–10%. Analysts were divided prior to the report; the consensus rating was Hold, though the average price target implies about 15% upside for the shares (source).
| 
